Dr. John Berk the Assistant Director of the Amyloidosis Center
John Berk, MD, Assistant Director of the center, specializes in familial transthyretin and lung amyloidosis. Dr. Berk designed and conducted the first international randomized controlled trial for familial amyloid polyneuropathy. This NIH- and FDA-funded study found that Diflunisal, an obsolete non-steroidal anti-inflammatory drug, inhibited neurologic disease progression, validated a neurologic metric to map disease progression, […]
U.S. Senate Committee on Appropriations: Amyloidosis Language
HOUSE APPROPRIATIONS COMMITTEE FISCAL YEAR 2022 LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION AMYLOIDOSIS REPORT LANGUAGE H. Rpt. 117-96 (accompany H.R. 4502) July 19, 2021 TITLE II—DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH OFFICE OF THE DIRECTOR (OD) Amyloidosis.—The Committee directs NIH to continue its expansion of research efforts in amyloidosis, a […]